$DYAI
DYADIC INTERNATIONAL INC Stock $dyai

$dyai Overview Financials Valuation SEC Filings Company Website

2021 Q1 Form 10-K Financial Statement

#000143774921007644 Filed on March 30, 2021

Income Statement

Concept	2021 Q1	2020	2019 Q4
Revenue	$460.5M	$1.602M	$430.0K
YoY Change	145924.38%	-4.71%	-37.68%
Cost Of Revenue	$390.8M	$1.425M	$420.0K
YoY Change	140369.91%	-2.38%	-17.65%
Gross Profit	$69.76M	$177.0K	$10.00K
YoY Change	187471.93%	-20.05%	-94.44%
Gross Profit Margin	15.15%	11.05%	2.33%
Selling, General & Admin	$1.550M	$6.080M	$1.160M
YoY Change	-6.06%	10.14%	-9.38%
% of Gross Profit	2.22%	3435.22%	11600.0%
Research & Development	$1.808B	$3.868M	$780.0K
YoY Change	239239.58%	25.28%	21.88%
% of Gross Profit	2591.96%	2185.5%	7800.0%
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses	$1.808B	$3.868M	$1.950M
YoY Change	239239.58%	25.28%	1.56%
Operating Profit	-$3.321B	-$10.03M	-$1.940M
YoY Change	139274.12%	8.01%	11.49%
Interest Expense	$25.67M	$447.0K	$210.0K
YoY Change	15145.01%	-54.62%	-8.7%
% of Operating Profit
Other Income/Expense, Net	$25.67M	$731.7K
YoY Change
Pretax Income	-$3.290M	-$9.246M	-$1.730M
YoY Change	48.87%	11.74%	13.82%
Income Tax		$31.32K	$10.00K
% Of Pretax Income
Net Earnings	-$3.295M	-$9.325M	-$1.740M
YoY Change	48.81%	12.24%	241.18%
Net Earnings / Revenue	-0.72%	-582.13%	-404.65%
Basic Earnings Per Share	-$0.12
Diluted Earnings Per Share	-$119.5K	-$339.6K	-$63.76K
COMMON SHARES
Basic Shares Outstanding	27.55M		27.21M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2021 Q1	2020	2019 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$27.23M	$29.09M	$34.22M
YoY Change	-12.95%	-14.99%	-16.94%
Cash & Equivalents	$13.06M	$20.64M	$4.824M
Short-Term Investments	$14.18M	$8.460M	$29.40M
Other Short-Term Assets	$220.0K	$280.0K	$100.0K
YoY Change	-24.14%	180.0%	-76.74%
Inventory
Prepaid Expenses
Receivables	$385.0K	$290.0K	$558.5K
Other Receivables	$160.0K	$120.0K	$750.0K
Total Short-Term Assets	$27.99M	$29.78M	$35.64M
YoY Change	-14.71%	-16.44%	-16.63%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$280.0K	$280.0K	$1.510M
YoY Change	-88.89%	-81.46%
Other Assets	$6.151K	$10.00K	$51.31K
YoY Change	-87.82%	-80.0%	-1.58%
Total Long-Term Assets	$290.9K	$290.0K	$1.813M
YoY Change	-88.68%	-83.98%	228.04%
TOTAL ASSETS
Total Short-Term Assets	$27.99M	$29.78M	$35.64M
Total Long-Term Assets	$290.9K	$290.0K	$1.813M
Total Assets	$28.28M	$30.07M	$37.45M
YoY Change	-20.08%	-19.71%	-13.51%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.474M		$943.4K
YoY Change	125.57%		205.24%
Accrued Expenses	$277.7K	$490.0K	$566.0K
YoY Change	15.69%	-14.04%	41.65%
Deferred Revenue	$842.2K		$78.64K
YoY Change	247.4%		-44.22%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$2.594M	$1.630M	$1.588M
YoY Change	128.36%	2.52%	86.91%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$0.00	$0.00	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$2.594M	$1.630M	$1.588M
Total Long-Term Liabilities	$0.00	$0.00	$0.00
Total Liabilities	$2.590M	$1.630M	$1.590M
YoY Change	127.19%	2.52%	87.06%
SHAREHOLDERS EQUITY
Retained Earnings	-$53.97M		-$41.35M
YoY Change	23.89%		25.14%
Common Stock	$39.81K		$39.61K
YoY Change	0.24%		1.66%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$18.90M		$18.93M
YoY Change	0.0%		0.16%
Treasury Stock Shares
Shareholders Equity	$25.69M	$28.45M	$35.86M
YoY Change
Total Liabilities & Shareholders Equity	$28.28M	$30.07M	$37.45M
YoY Change	-20.08%	-19.71%	-13.51%

Cashflow Statement

Concept	2021 Q1	2020	2019 Q4
OPERATING ACTIVITIES
Net Income	-$3.295M	-$9.325M	-$1.740M
YoY Change	48.81%	12.24%	241.18%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities	-$1.907B	-$6.574M	-$1.400M
YoY Change	95400.18%	13.69%	13.82%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities	-$5.780M	$22.12M	$1.340M
YoY Change	-440.0%	186.9%	-29.84%
Cash From Investing Activities	-$5.784B	$22.12M	$1.340M
YoY Change	-340809.76%	187.02%	-29.84%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$115.8M	$255.5K	220.0K
YoY Change	66071.43%	-53.57%
NET CHANGE
Cash From Operating Activities	-$1.907B	-$6.574M	-1.400M
Cash From Investing Activities	-$5.784B	$22.12M	1.340M
Cash From Financing Activities	$115.8M	$255.5K	220.0K
Net Change In Cash	-$7.581B	$15.81M	160.0K
YoY Change	5983095.88%	548.83%	-76.47%
FREE CASH FLOW
Cash From Operating Activities	-$1.907B	-$6.574M	-$1.400M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2021Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	27554157
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2019Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2019Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2019Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2020Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2020Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2019Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2019Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2019Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	39747659
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	39612659
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	27494157
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	27359157
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	-0
CY2019Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	51314	USD
CY2020Q4	us-gaap	Assets Assets	30072432	USD
CY2019Q4	us-gaap	Assets Assets	37452496	USD
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1013099	USD
CY2019Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	943378	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	489756	USD
CY2020Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	12253502
CY2019Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	12253502
CY2020	dyai	Number Of Research Organizations NumberOfResearchOrganizations	2	pure
CY2020	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	pure
CY2019Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0	USD
CY2017Q2	dyai	Collaborative Arrangement Duration Of Agreement CollaborativeArrangementDurationOfAgreement	P2Y
CY2017Q2	dyai	Collaborative Arrangement Payment For Research And Development Agreement CollaborativeArrangementPaymentForResearchAndDevelopmentAgreement	1000000	EUR
CY2020	dyai	Research And Development Expense Related Party ResearchAndDevelopmentExpenseRelatedParty	0	USD
CY2019	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	USD
CY2019	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	0	USD
CY2020	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	20637045	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4823544	USD
CY2020Q4	us-gaap	Held To Maturity Securities Current HeldToMaturitySecuritiesCurrent	8457452	USD
CY2019Q4	us-gaap	Held To Maturity Securities Current HeldToMaturitySecuritiesCurrent	29399146	USD
CY2020Q4	us-gaap	Interest Receivable Current InterestReceivableCurrent	112247	USD
CY2019Q4	us-gaap	Interest Receivable Current InterestReceivableCurrent	329711	USD
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	294199	USD
CY2019Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	558530	USD
CY2020Q4	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	0	USD
CY2019Q4	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	250308	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	280555	USD
CY2019Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	277999	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	29781498	USD
CY2019Q4	us-gaap	Assets Current AssetsCurrent	35639238	USD
CY2020Q4	us-gaap	Held To Maturity Securities Noncurrent HeldToMaturitySecuritiesNoncurrent	0	USD
CY2019Q4	us-gaap	Held To Maturity Securities Noncurrent HeldToMaturitySecuritiesNoncurrent	1511636	USD
CY2020Q4	us-gaap	Income Taxes Receivable Noncurrent IncomeTaxesReceivableNoncurrent	0	USD
CY2019Q4	us-gaap	Income Taxes Receivable Noncurrent IncomeTaxesReceivableNoncurrent	250308	USD
CY2020Q4	dyai	Prepaid Research And Development In Process Current PrepaidResearchAndDevelopmentInProcessCurrent	284709	USD
CY2019Q4	dyai	Prepaid Research And Development In Process Current PrepaidResearchAndDevelopmentInProcessCurrent	0	USD
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	6225	USD
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	566003	USD
CY2020Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	123016	USD
CY2019Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	78644	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1625871	USD
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1588025	USD
CY2020Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2019Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	39748	USD
CY2019Q4	us-gaap	Common Stock Value CommonStockValue	39613	USD
CY2020Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	98013079	USD
CY2019Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	96105851	USD
CY2020Q4	us-gaap	Treasury Stock Value TreasuryStockValue	18929915	USD
CY2019Q4	us-gaap	Treasury Stock Value TreasuryStockValue	18929915	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-50676351	USD
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-41351078	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	28446561	USD
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	37452496	USD
CY2019	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1171079	USD
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1601921	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	35864471	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	30072432	USD
CY2019	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1681076	USD
CY2020	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1424931	USD
CY2019	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1459701	USD
CY2020	dyai	Provision For Contract Losses ProvisionForContractLosses	187388	USD
CY2019	dyai	Provision For Contract Losses ProvisionForContractLosses	0	USD
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3868121	USD
CY2019	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3087597	USD
CY2020	dyai	Research And Development Expense Related Party ResearchAndDevelopmentExpenseRelatedParty	0	USD
CY2019	dyai	Research And Development Expense Related Party ResearchAndDevelopmentExpenseRelatedParty	868720	USD
CY2020	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6084799	USD
CY2019	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5519922	USD
CY2020	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	-62345	USD
CY2019	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	-27725	USD
CY2020	us-gaap	Costs And Expenses CostsAndExpenses	11627584	USD
CY2019	us-gaap	Costs And Expenses CostsAndExpenses	10963665	USD
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-10025663	USD
CY2019	us-gaap	Operating Income Loss OperatingIncomeLoss	-9282589	USD
CY2020	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	446999	USD
CY2019	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	984930	USD
CY2020	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	284709	USD
CY2019	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	0	USD
CY2020	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-9293955	USD
CY2019	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-8297659	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	31318	USD
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	10306	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-9325273	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-8307965	USD
CY2020	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.34
CY2019	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.31
CY2020	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	27471587
CY2019	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	27003695
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	42451169	USD
CY2019	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	550188	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-8307965	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	35864471	USD
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1651893	USD
CY2020	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	255470	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-9325273	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	28446561	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-9325273	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-8307965	USD
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	1651893	USD
CY2019	us-gaap	Share Based Compensation ShareBasedCompensation	1171079	USD
CY2020	us-gaap	Investment Income Amortization Of Premium InvestmentIncomeAmortizationOfPremium	331277	USD
CY2019	us-gaap	Investment Income Amortization Of Premium InvestmentIncomeAmortizationOfPremium	198208	USD
CY2020	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	284709	USD
CY2019	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-0	USD
CY2020	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-62345	USD
CY2019	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-27725	USD
CY2020	us-gaap	Increase Decrease In Accrued Interest Receivable Net IncreaseDecreaseInAccruedInterestReceivableNet	-217464	USD
CY2019	us-gaap	Increase Decrease In Accrued Interest Receivable Net IncreaseDecreaseInAccruedInterestReceivableNet	35471	USD
CY2020	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-363365	USD
CY2019	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	252772	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2386314	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	20637045	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4823544	USD
CY2020	us-gaap	Proceeds From Income Tax Refunds ProceedsFromIncomeTaxRefunds	500616	USD
CY2020	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	-500616	USD
CY2019	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	-506866	USD
CY2020	dyai	Increase Decrease In Prepaid Research And Development IncreaseDecreaseInPrepaidResearchAndDevelopment	-0	USD
CY2019	dyai	Increase Decrease In Prepaid Research And Development IncreaseDecreaseInPrepaidResearchAndDevelopment	-253446	USD
CY2020	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2410	USD
CY2019	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	105707	USD
CY2020	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-53200	USD
CY2019	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	657658	USD
CY2020	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-80132	USD
CY2019	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	166399	USD
CY2020	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	44372	USD
CY2019	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-62358	USD
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-6574392	USD
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-5782892	USD
CY2020	us-gaap	Payments To Acquire Held To Maturity Securities PaymentsToAcquireHeldToMaturitySecurities	17638947	USD
CY2019	us-gaap	Payments To Acquire Held To Maturity Securities PaymentsToAcquireHeldToMaturitySecurities	47615550	USD
CY2020	us-gaap	Proceeds From Sale And Maturity Of Held To Maturity Securities ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities	39761000	USD
CY2019	us-gaap	Proceeds From Sale And Maturity Of Held To Maturity Securities ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities	55323000	USD
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	22122053	USD
CY2019	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	7707450	USD
CY2020	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	255470	USD
CY2019	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	550188	USD
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	255470	USD
CY2019	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	550188	USD
CY2020	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	10370	USD
CY2019	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-37516	USD
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	15813501	USD
CY2019	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	2437230	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4823544	USD
CY2019	us-gaap	Proceeds From Income Tax Refunds ProceedsFromIncomeTaxRefunds	506866	USD
CY2020	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"><b><i>Use of Estimates </i></b></p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">The preparation of these consolidated financial statements in accordance with GAAP requires management to make estimates and judgments that affect the reported amount of assets and liabilities and related disclosure of contingent assets and liabilities at the date of our consolidated financial statements and the reported amounts of revenues and expenses during the applicable period. Actual results <em style="font: inherit;"> may </em>differ from these estimates under different assumptions or conditions. Such differences could be material to the consolidated financial statements.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"> </p>
CY2020	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"><b><i>Concentrations and Credit Risk</i></b></p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">The Company’s financial instruments that are potentially subject to concentrations of credit risk consist primarily of cash and cash equivalents, investment securities, and accounts receivable. At times, the Company has cash, cash equivalents, and investment securities at financial institutions exceeding the Federal Depository Insurance Company (“FDIC”) and the Securities Investor Protection Corporation (“SIPC”) insured limit on domestic currency and the Netherlands FDIC counterpart for foreign currency. The Company only deals with reputable financial institutions and has <em style="font: inherit;">not</em> experienced any losses in such accounts.</p> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"> </p> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">For the years ended <em style="font: inherit;"> December 31, 2020 </em>and <em style="font: inherit;">2019</em>, the Company’s revenue was generated from <span style="-sec-ix-hidden:c71724213">fourteen</span> and <span style="-sec-ix-hidden:c71724214">ten</span> customers, respectively. At <em style="font: inherit;"> December 31, 2020 </em>and <em style="font: inherit;">2019</em>, the Company’s accounts receivable was from <span style="-sec-ix-hidden:c71724216">nine</span> and <span style="-sec-ix-hidden:c71724217">five</span> customers, respectively. The loss of business from <em style="font: inherit;">one</em> or a combination of the Company’s customers could adversely affect its operations.</p> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">The Company conducts operations in the Netherlands through its foreign subsidiary and generates a portion of its revenues from customers that are located outside of the United States. As of and for the year ended <em style="font: inherit;"> December 31, 2020</em>, the Company had <span style="-sec-ix-hidden:c71724219">seven</span> customers outside of the United Sates (i.e. European and Asian customers) that accounted for approximately 49.7% or $796,000 of total revenue and approximately 41.6% or $123,000 of accounts receivable. As of and for the year ended <em style="font: inherit;"> December 31, 2019</em>, the Company only had <span style="-sec-ix-hidden:c71724224">four</span> customers outside of the United Sates (i.e. European and Asian customers) that accounted for approximately 71.5% or $1,202,000 of total revenue and approximately 69.5% or $388,000 of accounts receivable.</p> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"> </p> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">The Company uses several contract research organizations (“CROs”) to conduct its research projects. For the years ended <em style="font: inherit;"> December 31, 2020 </em>and <em style="font: inherit;">2019</em>, <em style="font: inherit;">one</em> CRO accounted for approximately 91.6% and 86.6% of total research services we purchased, respectively. At <em style="font: inherit;"> December 31, 2020</em>, approximately $690,000 or 68.1% of accounts payable was related to this CRO. At <em style="font: inherit;"> December 31, 2019</em>, approximately $706,000 or 74.9% of accounts payable was related to this CRO. The loss of business from this CRO or a combination of the Company’s CROs could adversely affect its operations.</p> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"> </p>
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	566003	USD
CY2020Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0	USD
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	294199	USD
CY2019Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	558530	USD
CY2020Q4	us-gaap	Prepaid Insurance PrepaidInsurance	204988	USD
CY2019Q4	us-gaap	Prepaid Insurance PrepaidInsurance	173890	USD
CY2020Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	72403	USD
CY2019Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	101221	USD
CY2020Q4	us-gaap	Prepaid Taxes PrepaidTaxes	3164	USD
CY2019Q4	us-gaap	Prepaid Taxes PrepaidTaxes	2888	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	280555	USD
CY2019Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	277999	USD
CY2020Q4	dyai	Research And Development In Process Current ResearchAndDevelopmentInProcessCurrent	904572	USD
CY2019Q4	dyai	Research And Development In Process Current ResearchAndDevelopmentInProcessCurrent	766001	USD
CY2020Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	24496	USD
CY2019Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	26994	USD
CY2020Q4	us-gaap	Accounts Payable Other Current AccountsPayableOtherCurrent	84031	USD
CY2019Q4	us-gaap	Accounts Payable Other Current AccountsPayableOtherCurrent	150383	USD
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1013099	USD
CY2019Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	943378	USD
CY2020Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	447881	USD
CY2019Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	474388	USD
CY2020Q4	dyai	Accrued Research And Development In Process Current AccruedResearchAndDevelopmentInProcessCurrent	28508	USD
CY2019Q4	dyai	Accrued Research And Development In Process Current AccruedResearchAndDevelopmentInProcessCurrent	69795	USD
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	13367	USD
CY2019Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	21820	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	489756	USD
CY2020	dyai	Research And Development Expense Outside Contracted Services ResearchAndDevelopmentExpenseOutsideContractedServices	3302034	USD
CY2019	dyai	Research And Development Expense Outside Contracted Services ResearchAndDevelopmentExpenseOutsideContractedServices	2578507	USD
CY2020	dyai	Research And Development Expense Contracted Services Related Party ResearchAndDevelopmentExpenseContractedServicesRelatedParty	0	USD
CY2019	dyai	Research And Development Expense Contracted Services Related Party ResearchAndDevelopmentExpenseContractedServicesRelatedParty	868720	USD
CY2020	dyai	Research And Development Expense Personnel Related Costs ResearchAndDevelopmentExpensePersonnelRelatedCosts	531405	USD
CY2019	dyai	Research And Development Expense Personnel Related Costs ResearchAndDevelopmentExpensePersonnelRelatedCosts	423898	USD
CY2020	dyai	Research And Development Expense Facilities Overhead And Other ResearchAndDevelopmentExpenseFacilitiesOverheadAndOther	34682	USD
CY2019	dyai	Research And Development Expense Facilities Overhead And Other ResearchAndDevelopmentExpenseFacilitiesOverheadAndOther	85192	USD
CY2020	dyai	Research And Development Expense Including Related Party ResearchAndDevelopmentExpenseIncludingRelatedParty	3868121	USD
CY2019	dyai	Research And Development Expense Including Related Party ResearchAndDevelopmentExpenseIncludingRelatedParty	3956317	USD
CY2019	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	0
CY2020	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4638390
CY2019	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3860390
CY2020Q4	us-gaap	Cash Cash	149015	USD
CY2020Q4	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	20488030	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	20637045	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	20637045	USD
CY2020Q4	dyai	Cash Cash Equivalents And Investments Fair Value CashCashEquivalentsAndInvestmentsFairValue	29110506	USD
CY2020Q4	us-gaap	Held To Maturity Securities Accumulated Unrecognized Holding Gain HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain	22473	USD
CY2020Q4	us-gaap	Held To Maturity Securities Accumulated Unrecognized Holding Loss HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss	6463	USD
CY2020Q4	us-gaap	Investments And Cash InvestmentsAndCash	29094496	USD
CY2019Q4	us-gaap	Cash Cash	1010510	USD
CY2019Q4	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	3813034	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	4823544	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4823544	USD
CY2019Q4	dyai	Cash Cash Equivalents And Investments Fair Value CashCashEquivalentsAndInvestmentsFairValue	35738787	USD
CY2019Q4	us-gaap	Held To Maturity Securities Accumulated Unrecognized Holding Gain HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain	22452	USD
CY2019Q4	us-gaap	Held To Maturity Securities Accumulated Unrecognized Holding Loss HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss	17991	USD
CY2019Q4	us-gaap	Investments And Cash InvestmentsAndCash	35734326	USD
CY2017Q2	dyai	Collaborative Arrangement Payment For Research And Development Agreement CollaborativeArrangementPaymentForResearchAndDevelopmentAgreement	1100000	USD
CY2019	dyai	Research And Development Expense Related Party ResearchAndDevelopmentExpenseRelatedParty	900000	USD
CY2020	dyai	Tax Cuts And Jobs Act Change In Alternative Minimum Tax Income Tax Benefit TaxCutsAndJobsActChangeInAlternativeMinimumTaxIncomeTaxBenefit	1001233	USD
CY2018	us-gaap	Proceeds From Income Tax Refunds ProceedsFromIncomeTaxRefunds	500000	USD
CY2019	us-gaap	Proceeds From Income Tax Refunds ProceedsFromIncomeTaxRefunds	500000	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-9246122	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-8274712	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-47833	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-22947	USD
CY2020	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-9293955	USD
CY2019	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-8297659	USD
CY2020	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	0	USD
CY2020	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.2100	pure
CY2019	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.2100	pure
CY2020	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.0360	pure
CY2019	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.0461	pure
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.0045	pure
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.0649	pure
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.2419	pure
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.3099	pure
CY2020	dyai	Effective Income Tax Rate Reconciliation Trueup Adjustment Percent EffectiveIncomeTaxRateReconciliationTrueupAdjustmentPercent	0.0133	pure
CY2019	dyai	Effective Income Tax Rate Reconciliation Trueup Adjustment Percent EffectiveIncomeTaxRateReconciliationTrueupAdjustmentPercent	0.0018	pure
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.0013	pure
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.0007	pure
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0	pure
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0.0100	pure
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	-0.0034	pure
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	0	pure
CY2020	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
CY2019	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	-0
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	689600	USD
CY2019Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	275000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	7080600	USD
CY2019Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	5214200	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	1656500	USD
CY2019Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	1656500	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities Investments DeferredTaxLiabilitiesInvestments	69800	USD
CY2019Q4	us-gaap	Deferred Tax Liabilities Investments DeferredTaxLiabilitiesInvestments	-0	USD
CY2020Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	7900	USD
CY2019Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	4400	USD
CY2020Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	9364800	USD
CY2019Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	7150100	USD
CY2020Q4	dyai	Deferred Tax Assets Net Of Liabilities Before Valuation Allowance DeferredTaxAssetsNetOfLiabilitiesBeforeValuationAllowance	9364800	USD
CY2019Q4	dyai	Deferred Tax Assets Net Of Liabilities Before Valuation Allowance DeferredTaxAssetsNetOfLiabilitiesBeforeValuationAllowance	7150100	USD
CY2020Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2019Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2020Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	27300000	USD
CY2019Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	19700000	USD
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	USD
CY2020Q4	us-gaap	Purchase Obligation Due In Next Twelve Months PurchaseObligationDueInNextTwelveMonths	2458506	USD
CY2020Q4	us-gaap	Purchase Obligation Due In Second Year PurchaseObligationDueInSecondYear	771075	USD
CY2020Q4	us-gaap	Purchase Obligation Due In Third Year PurchaseObligationDueInThirdYear	0	USD
CY2020Q4	us-gaap	Purchase Obligation PurchaseObligation	3229581	USD
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0025	pure
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0172	pure
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0169	pure
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0250	pure
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.3994	pure
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.5122	pure
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.2859	pure
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.3729	pure
CY2020	dyai	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Discount For Lack Of Marketability SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsDiscountForLackOfMarketability	0	pure
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3552890
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.57
CY2018	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P5Y21D
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	1149461	USD
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1089000
CY2019	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	2.26
CY2019	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	781500
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	1.89
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	2.09
CY2019	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	1.60
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.69
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	481139	USD
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	2925662	USD
CY2020Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	477232	USD
CY2019Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	222330	USD
CY2020	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y10M2D
CY2019	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y9M29D
CY2019	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	0
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3860390
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.76
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P5Y8M8D
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	13287932	USD
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	913000
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	5.24
CY2020	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	135000
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	1.89
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	-0
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	0
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	-0
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	0
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	4638390
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.44
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P5Y7M20D
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	13701610	USD
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	3284794
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	1.78
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P4Y5M19D
CY2020Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	11886680	USD
CY2020	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	135000
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1651893	USD
CY2019	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1171079	USD
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	1.89
CY2019	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	1.60
CY2020Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	12253502
CY2020Q4	us-gaap	Treasury Stock Value TreasuryStockValue	18900000	USD
CY2020Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001

Files In Submission

Name	View Source	Status
0001437749-21-007644-index-headers.html	Edgar Link	pending
0001437749-21-007644-index.html	Edgar Link	pending
0001437749-21-007644.txt	Edgar Link	pending
0001437749-21-007644-xbrl.zip	Edgar Link	pending
dyai-20201231.xsd	Edgar Link	pending
dyai-20201231_cal.xml	Edgar Link	unprocessable
dyai-20201231_def.xml	Edgar Link	unprocessable
dyai-20201231_lab.xml	Edgar Link	unprocessable
dyai-20201231_pre.xml	Edgar Link	unprocessable
dyai20201008_10k.htm	Edgar Link	pending
dyai20201008_10kimg001.jpg	Edgar Link	pending
dyai20201008_10kimg002.jpg	Edgar Link	pending
dyai20201008_10kimg003.jpg	Edgar Link	pending
dyai20201008_10k_htm.xml	Edgar Link	completed
ex_216709.htm	Edgar Link	pending
ex_216710.htm	Edgar Link	pending
ex_218886.htm	Edgar Link	pending
ex_218887.htm	Edgar Link	pending
ex_223824.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$DYAI
DYADIC INTERNATIONAL INC Stock $dyai

2021 Q1 Form 10-K Financial Statement

#000143774921007644 Filed on March 30, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$DYAI DYADIC INTERNATIONAL INC Stock $dyai

2021 Q1 Form 10-K Financial Statement

#000143774921007644 Filed on March 30, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$DYAI
DYADIC INTERNATIONAL INC Stock $dyai